Compass Therapeutics Inc
NASDAQ:CMPX 11:49:43 AM EDT
Earnings Announcements
Compass Therapeutics Reports First Quarter 2022 Financial Results
Published: 05/09/2022 13:47 GMT
Compass Therapeutics Inc (CMPX) - Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress.
$136.4 Million in Cash and Cash Equivalents at End of Q1.
Anticipated Cash Runway Into Second Half of 2024.
Net Loss for Q1 Ended March 31, 2022 $0.07 per Common Share.
Q1 Earnings per Share View $-0.12 -- Refinitiv Ibes Data (analyst estimates).
$136.4 Million in Cash and Cash Equivalents at End of Q1.
Anticipated Cash Runway Into Second Half of 2024.
Net Loss for Q1 Ended March 31, 2022 $0.07 per Common Share.
Q1 Earnings per Share View $-0.12 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.08
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.09
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.08
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.09
More details on our Analysts Page.